Treating asthma in the time of COVID.

"Disclosure of potential conflict of interest: T. F. Carr has served in an advisory role or as a consultant for AstraZeneca, Genentech, GlaxoSmithKline (GSK), Novartis, and Regeneron and as a writer and editor for Wolters Kluwer UpToDate. M. Kraft has received research funding paid to her institution from the 10.13039/100000002National Institutes of Health, ALA, 10.13039/100004339Sanofi, 10.13039/100004325AstraZeneca, Synairgen, and Janssen; served on an advisory board for 10.13039/100004325AstraZeneca, 10.13039/100004339Sanofi, 10.13039/100019719Chiesi, and Synairgen; has received fees for speaking for 10.13039/100019719Chiesi, 10.13039/100004325AstraZeneca, and Sanofi; is cofounder and CMO, RaeSedo, Inc, a company evaluating peptidomimetics for treatment of inflammatory lung disease; and payments from Elsevier for UptoDate, where she is a section editor for asthma. W. Phipatanakul has served in advisory capacity for Genentech, Novartis, Sanofi, Regenron, Teva, Astra Zeneca, and GSK. S. J. Szefler reports consultant fees paid to the university from 10.13039/100004325AstraZeneca, GSK, Moderna, OM Pharma, Propeller Health, 10.13039/100009857Regeneron Pharmaceuticals, Inc, and 10.13039/100004339Sanofi. A. A. Zeki reports serving as CSO for InStatin, Inc; and on Sanofi/Regeneron consulting and advisory boards. D. P. Beden has served as a consultant for Teva and 10.13039/100004330GSK and receives grant support from the 10.13039/100000050National Heart, Lung, and Blood Institute, National Institute of Environmental Health Sciences, 10.13039/100000060National Institute of Allergy and Infectious Diseases, Department of Defense, and Environmental Protection Agency. S. R. White has served as a consultant and speaker for AstraZeneca, Sanofi, and Regeneron. M. L. Fajt has no relevant conflicts of interest."

"The PrecISE Asthma study is funded by the 10.13039/100000050National Heart, Lung, and Blood Institute, National Institutes of Health (grant nos. U24 HL138998, 1UG1HL139054, 1UG1HL139098, 1UG1HL139106, 1UG1HL139117, 1UG1HL139118, 1UG1HL139119, 1UG1HL139123, 1UG1HL139124, 1UG1HL139125, 1UG1HL139126, and 1UG1HL146002). Support for site institutional infrastructure came from National Institute of Health Clinical & Translational Science Award (grant nos. UL1TR002451 [Harvard], UL1TR000427 [University of Wisconsin], UL1TR002366 [University of Kansas], UL1TR002389 [University of Chicago], UL1TR002489 [University of North Carolina], UL1TR002548 [Cleveland Clinic], and UL1TR001442 [University of California, San Diego]). The study also gratefully acknowledges receiving contributed product from Vitaeris, owned and operated by the CSL Group (clazakizumab), Vitaflo (MCT), Sun Pharma (imatinib), OM Pharma, a Vifor Pharma Group Company (OM-85, BronchoVaxom), Incyte (itacitinib), Laurel Venture (cavosonstat), and GlaxoSmithKline (Advair Diskus and Ventolin)."